InflaRx (IFRX) Other Operating Expenses (2016 - 2026)
InflaRx's (IFRX) quarterly Other Operating Expenses came in at -$35073.1 in Q2 2026, up 96.94% year-over-year from -$17808.8 in Q2 2025, and up 72.28% quarter-over-quarter from -$126524.8 in Q1 2026.
Analysis
InflaRx (IFRX) Other Operating Expenses (2016 - 2026) Analysis & Trends
InflaRx has disclosed Other Operating Expenses across 11 years of filings, most recently posting -$35073.1 for Q2 2026.
- In Q2 2026, Other Operating Expenses rose 96.94% year-over-year to -$35073.1; the TTM figure through Jun 2026 stood at -$1.5 million (up 66.44% YoY), while the FY2020 annual figure was -$61245.9 billion, down 7901870346.72% from the prior year.
- Other Operating Expenses came in at -$35073.1 for Q2 2026 at InflaRx, up from -$126524.8 in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of -$1.01 in Q3 2022 to a low of -$53456.5 billion in Q4 2022.
- Average Other Operating Expenses over 5 years is -$4859.7 billion, with a median of -$1.5 million recorded in 2025.
- Year-over-year, Other Operating Expenses tumbled 54131316000.0% in 2022 and soared 96.94% in 2026.
- Over 5 years, Other Operating Expenses stood at -$53456.5 billion in 2022, then soared by 100.0% to -$1.7 million in 2023, then dropped by 10.26% to -$1.9 million in 2024, then gained by 27.1% to -$1.4 million in 2025, then soared by 97.43% to -$35073.1 in 2026.
- Per Business Quant data, the three most recent Other Operating Expenses figures were -$35073.1 in Q2 2026, -$126524.8 in Q1 2026, and -$1.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35,073.11 |
| Mar 31, 2026 | -126,524.82 |
| Sep 30, 2025 | -1.37 Mn |
| Jun 30, 2025 | -1.15 Mn |
| Mar 31, 2025 | -1.53 Mn |
| Sep 30, 2024 | -1.88 Mn |
| Mar 31, 2024 | -1.59 Mn |
| Sep 30, 2023 | -1.70 Mn |
| Dec 31, 2022 | -53,456.47 Bn |
| Sep 30, 2022 | -1.01 |
| Jun 30, 2022 | -23.86 Mn |
| Dec 31, 2021 | -54,547.52 Bn |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | -27.21 Mn |
| Mar 31, 2021 | -1.21 |
| Dec 31, 2020 | -30,622.91 Bn |
| Mar 31, 2020 | 1.10 |
| Dec 31, 2019 | 0.01 |
| Jun 30, 2019 | 0.00 |
| Dec 31, 2018 | -199,123.45 |